Related by context. All words. (Click for frequent words.) 71 Oncotype DX Recurrence Score 66 platelet reactivity 65 neoadjuvant chemotherapy 65 KRAS mutations 63 CIN2 + 63 biochemical recurrence 63 preoperative chemotherapy 63 HER2 expression 63 HERmark 62 distant metastases 62 multivariate analyzes 62 multivariable analysis 62 Kaplan Meier analysis 62 neoadjuvant 62 pCR 62 adjuvant radiation 62 tumor recurrence 61 tumor histology 61 EUS FNA 61 stratify patients 61 lymph node metastasis 61 mammographic density 61 pancreatic adenocarcinoma 61 univariate 61 advanced adenomas 61 distant metastasis 61 clinically localized prostate 61 HER2 positive metastatic breast 61 postoperative chemotherapy 61 IL#B 61 estrogen receptor ER 61 PSADT 61 PSA nadir 61 operable breast cancer 61 HSCT 61 adjuvant chemotherapy 60 virological response 60 adjuvant therapy 60 lumbar spine BMD 60 undetectable HBV DNA 60 #.#ng/ml 60 lymph node involvement 60 SUVmax 60 non squamous NSCLC 60 HER2 overexpression 60 multivariate Cox 60 virologic responses 60 PROLARIS 60 decitabine 60 sustained virological response 60 KRAS mutation 60 FDG PET 60 prognostic variables 60 Reynolds Risk Score 60 debulking surgery 60 statistical significance p 60 virologic response 60 myocardial viability 60 HER2 negative 60 atypia 60 advanced adenoma 59 KRAS status 59 PSA velocity 59 HBeAg seroconversion 59 A1c levels 59 OncotypeDX 59 virologic failure 59 atypical hyperplasia 59 EpCAM expression 59 prognostic factors 59 Logistic regression 59 mRNA expression 59 thyroglobulin 59 EBRT 59 prospectively defined 59 epithelial tumors 59 CCyR 59 hormone receptor positive 59 cystatin C 59 biochemical relapse 59 pretest probability 59 contralateral breast cancer 59 univariate analysis 59 atherothrombotic disease 59 PCA3 59 histological subtype 59 KIF6 carriers 59 sustained virologic response 59 angiographic outcomes 59 troponin T 59 locoregional 59 complete cytogenetic 59 complete cytogenetic response 59 taxane therapy 59 progesterone receptor PR 59 baseline HbA1c 59 clinicopathological features 58 clinico pathological 58 histopathologic 58 mRCC 58 definite stent thrombosis 58 postoperative radiotherapy 58 radiochemotherapy 58 nonfasting triglyceride levels 58 adjuvant radiotherapy 58 Doxil ® 58 EGFR mutations 58 HBeAg negative patients 58 Framingham Risk Score 58 GSTP1 58 deCODE BreastCancer TM 58 tirofiban 58 cTnT 58 dose cytarabine 58 genotypic resistance 58 CIN3 58 rs# [001] 58 lymph node metastases 58 hip BMD 58 prognostic indicators 58 Oncotype DX 58 axillary dissection 58 baseline LDH 58 miRview mets 58 serum uric acid 58 SLNB 58 rs# [002] 58 grade cervical intraepithelial 58 MADRS score 58 androgen deprivation 58 advanced neoplasia 58 immunostaining 58 MGd 58 DAS# scores 58 TMPRSS2 ERG 58 histological subtypes 58 K ras mutations 58 PCa 58 FDG uptake 58 nodal metastases 58 lymphocyte count 58 Lp PLA2 58 antigen PSA 58 MMSE score 58 neoadjuvant treatment 58 circulating EPCs 58 carotid IMT 58 CYP#D# genotype 58 anastrozole 58 VKORC1 58 serum creatinine levels 58 epithelial ovarian cancer 58 bivariate 58 BENICAR HCT 58 YMRS 58 Multivariate analysis 58 prostate biopsy 57 logistic regression analysis 57 serum prostate 57 intraobserver 57 HOMA IR 57 BRCA mutations 57 predictive biomarker 57 TOP2A 57 hormone receptor negative 57 fluvastatin 57 chemoradiotherapy 57 carotid stenosis 57 multivariate logistic regression 57 #F FDG PET 57 subclinical atherosclerosis 57 breast carcinomas 57 #p# [001] 57 sensitivity specificity 57 breast cancer recurrence 57 logistic regression analyzes 57 locoregional recurrence 57 Response Evaluation Criteria 57 specific antigen PSA 57 HGPIN 57 serum concentrations 57 XIENCE V PROMUS Stent 57 serum estradiol 57 ovarian carcinoma 57 cTnI 57 neoadjuvant therapy 57 UGT#A# * 57 node metastases 57 hsCRP 57 LV dysfunction 57 PSA kinetics 57 lipid lowering drugs 57 allele frequencies 57 immunohistochemical 57 estrogen receptor negative 57 prognostic markers 57 surrogate endpoint 57 prognostic factor 57 D dimer 57 breast cancer subtypes 57 EpCAM 57 urine albumin 57 Oncotype DX breast cancer 57 standard chemotherapy regimen 57 HBeAg 57 FDG-PET/CT 57 thyrotropin levels 57 CIMZIA ™ 57 serum clusterin levels 57 BRCA1 mutation carriers 57 NIHSS score 57 HBeAg positive patients 57 ERCC1 57 endoscopic remission 57 KRAS mutations occur 57 HNSCC 57 preoperative PSA 57 chemosensitivity 57 p# biomarker 57 adjuvant tamoxifen 57 axillary lymph nodes 57 PCA3 scores 57 cytogenetic 57 BRCA2 mutation carriers 57 Lp PLA 2 57 HER-2/neu 57 fosamprenavir 57 chemoradiation 57 postoperative complication 57 VIDAZA 57 biopsy Gleason 57 histologic subtypes 57 oncologic outcomes 57 external beam radiotherapy 57 lymphadenectomy 57 ErbB2 positive 57 TT genotype 57 eTag assays 57 bladder carcinoma 57 curative resection 57 nonmetastatic 57 eGFR 57 Subgroup analyzes 57 prostate cancer CaP 57 probands 57 Her2/neu 57 CaP 57 MetS 57 pertuzumab 57 eplerenone 57 BRCA mutation 57 urothelial carcinoma 57 ependymoma 57 alanine aminotransferase ALT 57 NCCN guidelines 57 CR nPR 57 mycophenolate mofetil 57 tPSA 57 Immunohistochemistry 57 SLN biopsy 56 NNRTI resistance 56 Flu Cy 56 mg/m2 dose 56 Ki# 56 QTc prolongation 56 HOXB# 56 FOLPI 56 adjuvant hormonal therapy 56 TIMP 1 56 hydroxyvitamin D levels 56 gene expression profiles 56 trastuzumab 56 radical nephrectomy 56 gefitinib Iressa 56 BI RADS 56 serum PSA 56 ezetimibe simvastatin 56 RECIST Response Evaluation Criteria 56 glycated hemoglobin levels 56 low expressors 56 multivariable logistic regression 56 ABCB1 56 neutrophil counts 56 mutated K ras 56 hematologic toxicity 56 PASI scores 56 NAbs 56 metastatic renal cell carcinoma 56 Bonferroni correction 56 azacitidine 56 intact parathyroid hormone 56 HER2 + 56 patients undergoing CABG 56 DAS# CRP 56 XELOX 56 adenoma recurrence 56 serum HCV RNA 56 invasive ductal 56 HbA1c levels 56 HbA 1c 56 sUA 56 trastuzumab Herceptin ® 56 conditional logistic regression 56 5 HTTLPR 56 hepatocellular carcinomas 56 HbA 1C 56 clinicopathological 56 nomogram 56 fine needle aspiration 56 malignant lesions 56 PITX2 56 immunohistochemical staining 56 insulin glargine 56 contralateral breast 56 Subgroup analysis 56 radical prostatectomy RP 56 antiangiogenic therapy 56 RE LY 56 colorectal cancer CRC 56 Zevalin consolidation 56 dyslipidaemia 56 bivariate analysis 56 perioperative mortality 56 log# copies mL 56 RRM1 56 poor metabolizers 56 EGFR mutation status 56 NGAL 56 asymptomatic carotid stenosis 56 HIV RNA 56 lymphovascular invasion 56 serum urate levels 56 nonfatal MI 56 glomerular filtration rate 56 colorectal neoplasia 56 dose melphalan 56 dose dexamethasone 56 histologic 56 FOLFOX4 56 VADT 56 kidney allograft 56 folate intake 56 vertebral fracture 56 estrogen receptor positive 56 MammaPrint R 56 ARB telmisartan 56 glycated hemoglobin HbA1c 56 breast carcinoma 56 androgen suppression 56 HbA 1c levels 56 HORIZONS AMI trial 56 p = .# [002] 56 SCCHN 56 PTPN# 56 penetrance 56 CR CRu 56 Prostate specific antigen 56 tHcy 56 cystectomy 56 proton MR spectroscopy 56 iPTH 56 telomere lengths 56 CC genotype 56 microarray experiments 56 cervical carcinoma 56 postoperative mortality 56 underwent resection 56 Crohn Disease Activity 56 serum urate 55 miRview squamous 55 troponins 55 gemcitabine carboplatin 55 symptomatic VTE 55 logistic regression models 55 intima media thickness 55 renal tumors 55 virological failure 55 Renal Cell Carcinoma RCC 55 estimated glomerular filtration 55 DEXA scan 55 COPAXONE ® 55 endocrine therapy 55 colorectal adenoma 55 sentinel lymph node biopsy 55 B7 H3 55 BRAF mutation 55 Cervista HPV HR 55 Oncotype DX colon cancer 55 HER2 positive cancers 55 allogeneic stem cell 55 standard chemotherapy regimens 55 recurrent VTE 55 catheter angiography 55 cTnT levels 55 histologically confirmed 55 univariate analyzes 55 atherogenic dyslipidemia 55 oral Xeloda 55 dosage regimens 55 rs# [003] 55 histologic subtype 55 F FDG PET 55 IPSS 55 hyperintense lesions 55 exemestane Aromasin 55 logistic regression model 55 desvenlafaxine succinate 55 antitumor effect 55 gemcitabine Gemzar 55 multivariate regression analysis 55 DLQI 55 SWOG 55 adjuvant therapies 55 sonographic findings 55 dose clopidogrel 55 EGFR TKI 55 prostate cancer PCa 55 relapsed MM 55 genotypic 55 chemoradiation therapy 55 axillary node dissection 55 dacarbazine chemotherapy 55 methylation markers 55 Score TOS 55 homocysteine concentrations 55 abnormal Pap test 55 EBUS FNA 55 FLT3 55 depressive symptomatology 55 etiologic 55 progesterone receptor negative 55 invasive lobular carcinoma 55 remission CR 55 goserelin 55 lipid lowering therapy 55 HBsAg 55 mg kg dose 55 T1a 55 estrogen receptor progesterone receptor 55 tertiles 55 DNA methylation patterns 55 prostatic adenocarcinoma 55 tipranavir r 55 liver metastasis 55 COPAXONE R 55 pT3 55 peripheral blood mononuclear 55 microsatellite instability 55 microalbuminuria 55 CANCIDAS 55 SYNTAX trial 55 tumor subtypes 55 elevated ALT 55 multiple logistic regression 55 genetic polymorphisms 55 adnexal mass 55 endometrial carcinoma 55 APTIVUS r 55 axillary lymph node 55 atheroma volume 55 ICD therapy 55 chlamydial infection 55 epoetin beta 55 glycosylated hemoglobin levels 55 recurrent NSCLC 55 hormone receptor status 55 extracolonic findings 55 LVEF 55 ERBB2 55 AST ALT 55 oxycodone CR 55 creatinine ratio 55 medically inoperable 55 HER2 positive 55 cytogenetic response 55 STRIDE PD 55 radiotherapy RT 55 Neoadjuvant 55 subclinical hypothyroidism 55 CHADS2 55 BRCA2 mutation 55 pT2 55 NIHSS 55 mg BID dose 55 prognostic 55 gastric adenocarcinoma 55 residual platelet reactivity 55 antibody titer 55 rs# [004] 55 Multiple logistic regression 55 R0 resection 55 cervical intraepithelial neoplasia 55 ADPKD 55 MDRD equation 55 HER2 55 ANOVA 55 sarcosine 55 Cystatin C 55 exploratory endpoints 55 ImmuKnow 55 Regression analyzes 55 tamoxifen therapy 55 colorectal carcinomas 55 BRAF mutations 55 protease inhibitor PI 55 independent prognostic marker 55 urine NGAL 55 allogeneic SCT 55 FFR measurements 55 haematologic 55 prospectively randomized 55 qRT PCR 55 elevated LDH 55 convergent validity 55 NSABP B 55 WT1 55 ACRIN 55 FOLFOX6 54 poorer prognosis 54 undetectable viral load 54 cytoreductive surgery 54 periprocedural MI 54 clinically meaningful improvement 54 hsCRP levels 54 iniparib BSI 54 trials RCTs 54 adalimumab 54 adjuvant cisplatin 54 ROC curves 54 exhaled NO 54 antioxidant supplementation 54 adenocarcinomas 54 leukocyte count 54 Index CDAI 54 hepatic fibrosis 54 cardiac troponin T 54 linkage disequilibrium 54 doxorubicin docetaxel 54 SNP rs# [001] 54 KRAS wild 54 BRCA testing 54 femoral neck BMD 54 molecular biomarker 54 aldosterone antagonist 54 serum PTH 54 thyrotropin 54 interobserver 54 secondary efficacy endpoint 54 familial aggregation 54 antihypertensive therapy 54 NSTE ACS 54 ER CHOP 54 microRNA expression 54 axillary nodes 54 MDRD 54 Psoriasis Area 54 Mammostrat 54 situ LCIS 54 skin sterol 54 abnormal cytology 54 prognostic biomarker 54 composite endpoint 54 interobserver reliability 54 nondiabetic patients 54 T2DM 54 clusterin 54 TAXUS Stent 54 ALND 54 BRCA1 mutations 54 NMIBC 54 retrospective cohort 54 AVODART 54 QTc 54 serum cortisol 54 core needle biopsies 54 albumin excretion 54 SLC#A# [002] 54 TGFBR1 * 6A 54 coronary stenosis 54 multivariable analyzes 54 Coronary artery calcium 54 serum testosterone 54 GnRH agonists 54 atypical ductal hyperplasia 54 cranial radiation 54 patient subpopulations 54 elevated creatinine 54 underwent surgical resection 54 treat NNT 54 Group RTOG 54 ventricular tachyarrhythmia 54 serum vitamin D 54 Haptoglobin 54 hemoglobin A1c HbA1c 54 tumor lysis syndrome 54 abnormal glucose tolerance 54 nab paclitaxel 54 EGFR gene 54 cystatin 54 eribulin 54 baseline FEV 54 fasting insulin 54 ependymomas 54 HER2 gene 54 comorbidity 54 cilostazol 54 Solid Tumors RECIST 54 grade gliomas 54 HIV tropism 54 transgene expression 54 Velcade bortezomib 54 aldosterone antagonists 54 secondary efficacy endpoints 54 HDRS 54 serum leptin 54 meta regression 54 tipranavir 54 relapsed SCLC 54 CYP#C# [001] 54 miRview ™ squamous 54 unresectable tumors 54 dose Iluvien 54 adjuvant endocrine therapy 54 K ras 54 APTIMA HPV 54 BRCA mutation carriers 54 UGT#A# 54 HAM D 54 NPH insulin 54 grade glioma 54 insulin detemir 54 metastatic RCC 54 PARP inhibition 54 carboplatin paclitaxel 54 proband 54 abdominal adiposity 54 eosinophil count 54 trabectedin 54 everolimus eluting stents 54 ECOG 54 clinicopathologic 54 PITX2 methylation 54 metabolic parameters 54 serum phosphorus 54 hENT1 54 BRCA2 mutations 54 antihypertensive agents 54 papillary renal cell carcinoma 54 symptomatic intracerebral hemorrhage 54 EGFR mutation 54 odds ratios ORs 54 multivariable adjusted 54 preoperative radiotherapy 54 stratifying patients 54 colon capsule endoscopy 54 carotid intima media 54 HbA1C 54 metastatic malignant 54 tumor biopsies 54 antitumor activity 54 IFN α 54 Immunohistochemistry IHC 54 viral kinetics 54 imatinib therapy 54 nomograms 54 CTAP# Capsules 54 metastatic CRC 54 receiving Vectibix monotherapy 54 splice variants 54 BCIRG 54 recurrent ovarian cancer 54 maternal serum 54 RBP4 levels 54 prostate carcinoma 54 adenotonsillectomy 54 resected pancreatic cancer 54 CVD mortality 54 PON1 enzyme 54 nephrectomy 54 lobular carcinomas 54 TRAIL R1 54 postintervention 54 gene expression patterns 54 MADIT CRT trial 54 Severity MSCS score 54 seroconversion 54 colorectal adenomas 54 micrometastases 54 ACR# responses 54 urine cytology 54 CNS LS 54 endometrial cancers 54 HER2 amplified 54 HAQ DI 54 HAART regimens 54 5-fluorouracil/leucovorin 54 morphometric vertebral fractures 54 Histologic 54 obstructive coronary artery 54 chromosomal aberrations 54 Pharmacokinetic parameters 54 castration resistant prostate cancer 54 HER2 amplification 54 INTELENCE 54 NATRECOR R 54 renal cell carcinomas 54 cetuximab 54 HBV DNA levels 54 prostate specific 54 myocardial necrosis 54 molecular subtypes 54 pegylated interferon alfa 2b 54 HERmark assay 54 PEG IFN 54 chlorambucil 54 transaminase levels 54 coronary artery calcium 54 Kaplan Meier estimates 54 completely resected 54 nodal metastasis 54 lymphopenia 54 recurrent glioblastoma multiforme 54 PCWP 54 allelic 54 response pCR 54 ELOXATIN 54 Hurthle cell 54 RECIST criteria 53 EDSS score 53 HRQOL 53 sentinel node biopsy 53 BEXXAR Therapeutic Regimen 53 % CI #.#-#.# [003] 53 hemoglobin concentrations 53 histopathologic findings 53 conventional angiography 53 lobular involution 53 elevated LDL cholesterol 53 HRQoL 53 TEAEs 53 RBC folate 53 irbesartan 53 Scale EDSS 53 Ejection Fraction 53 liver histology 53 prognostic significance 53 adenoma 53 infarct size 53 EBMT criteria 53 NATRECOR ® 53 specific antigen 53 Oncotype 53 plasma pharmacokinetics 53 angiographically 53 monozygotic 53 serum lipid levels 53 urothelial bladder cancer 53 thickness CIMT 53 serum ALT 53 xenograft models 53 HBeAg negative 53 FeNO 53 histologies 53 paclitaxel cisplatin 53 CIN3 + 53 ICD implantation 53 potent antiretroviral therapy 53 HbF 53 albumin excretion rate 53 ABVD 53 nonmetastatic prostate cancer 53 serum calcium levels 53 entecavir 53 noninferiority 53 Hb A1C 53 teriflunomide 53 tipranavir ritonavir 53 thyroid stimulating hormone 53 HAMD 53 serous ovarian cancer 53 achieved sustained virological 53 plasma folate 53 extrapyramidal symptoms 53 aminotransferase ALT 53 sDNA 53 CsA 53 baseline A1C 53 plasma homocysteine 53 ICD implantations 53 lymphocytosis 53 HNPCC 53 HER2 positive tumors 53 anti JCV antibodies 53 antiplatelet therapy 53 JAK2 V#F 53 warfarin dose 53 dose cohort 53 NYHA functional class 53 β blockers 53 PREZISTA r arm 53 ANCOVA 53 elevated CRP 53 revascularizations 53 HPV genotypes 53 response CCyR 53 LungExpress Dx 53 creatinine levels 53 titrated glipizide 53 resectable 53 #p# [003] 53 interferon alfa 53 invasive carcinomas 53 CYPHER Stent 53 thyroid carcinoma 53 atorvastatin #mg 53 estimated GFR 53 chemoembolization 53 EGFR inhibitors 53 SCIg 53 boosted protease inhibitor 53 CK # plasma concentrations 53 stable angina 53 Negative Syndrome 53 Estrogen Receptor 53 BARACLUDE ® 53 prospective multicentre 53 achieved ACR# 53 posttreatment 53 warfarin dosing 53 aminotransferases 53 thrombus aspiration 53 endothelin antagonists 53 hyperphenylalaninemia HPA due 53 ADCS CGIC 53 risk stratification 53 haplotypes 53 binary restenosis 53 serum IGF 53 stage IIIA 53 revascularization procedures 53 thiopurine 53 CORE OM 53 PNH patients 53 morphologic 53 abnormal p# biomarker 53 paricalcitol 53 familial AF 53 microarray analysis 53 GnRH agonist 53 ASCUS 53 OGTT 53 intravesical therapy 53 CRp 53 LV hypertrophy 53 oral FTY# 53 OnDose TM 53 CYP#C# [002] 53 unfractionated heparin 53 gene amplification 53 ADAS cog 53 atherosclerotic disease 53 NPM1 53 Gamma Imaging BSGI 53 Pearson correlation coefficients 53 immunohistochemistry IHC 53 esophageal squamous cell carcinoma 53 HRQL 53 trastuzumab Herceptin 53 confidence intervals CIs 53 International Prognostic Scoring 53 partial remissions 53 stenoses 53 DNA methylation markers 53 Metastatic colorectal cancer 53 EGFR TKIs 53 ZACTIMA 53 splenectomized patients 53 carotid plaque 53 CIN2 53 elevated triglyceride levels 53 TRUS 53 glycosylated hemoglobin 53 echocardiographic parameters 53 tertile 53 micrometastasis 53 carcinoembryonic antigen 53 #q# [001] 53 endometrial thickness 53 multivariable adjustment 53 fallopian tube carcinoma 53 IgG antibody 53 Lenalidomide 53 somatic mutations 53 immunoreactivity 53 UroVysion 53 GISTs 53 mesalamine granules 53 NT proBNP 53 recurrent miscarriage 53 VUR 53 Natalizumab 53 Kaplan Meier curve 53 dose cohorts 53 unpaired t 53 cardiac dysfunction 53 evaluable subjects 53 metabolite concentrations 53 transaminases 53 MAGE A3 ASCI 53 moderate renal impairment 53 cytogenetic abnormalities 53 serum selenium 53 perfusion abnormalities 53 hemoglobin A1c levels 53 coronary calcification 53 5-FU/LV 53 RE LY ® 53 adiponectin levels 53 lipid lowering agents 53 histologic diagnosis 53 EPDS 53 subclinical hyperthyroidism 53 statistically nonsignificant 53 thromboembolic 53 receiving VICTRELIS 53 FFR guided 53 peginterferon alfa 2a 53 euthymic patients 53 Her2 53 dose atorvastatin 53 abnormal mammogram 53 hamartomas 53 RTOG 53 systemic embolism 53 tolvaptan 53 FFR guided treatment 53 prednisone prednisolone 53 -#.# ± [002] 53 cytotoxic chemotherapy 53 antigen PSA levels 53 metastatic GIST 53 platelet inhibition 53 tumor regressions 53 intensive statin therapy 53 quantitative RT PCR 53 chemotherapy regimens 53 abnormal Pap 53 scintigraphic 53 R# #mg BID 53 miRNA expression 53 coronary artery stenosis 53 differential gene expression 53 transferrin saturation 53 lupus anticoagulant 53 mesothelin 53 pelvic lymphadenectomy 53 preoperatively 53 gastric carcinoma 53 dacarbazine DTIC 53 sunitinib 53 TroVax ® 53 sorafenib Nexavar 53 KRAS mutation status 53 SVR# 53 nonischemic 53 esophageal carcinoma 52 pharmacodynamic PD 52 Ceplene/IL-2 52 bisulfite sequencing 52 highest tertile 52 transaminase elevations 52 duplex ultrasonography 52 VT VF 52 oral antidiabetic medication 52 K#R [002] 52 ischemic cardiomyopathy 52 apolipoprotein B 52 dalteparin 52 Epigenomics proprietary 52 System IPSS 52 prostate adenocarcinoma 52 genomewide 52 MoxDuo TM IR 52 hematological parameters 52 IRESSA 52 Radical prostatectomy 52 metastatic lesions 52 lobular carcinoma 52 gene loci 52 certolizumab 52 CIMZIA TM 52 fluoropyrimidine 52 epoetin alpha 52 body fatness 52 concomitant medications 52 stage IIIB 52 prospective observational cohort 52 Thrombolysis 52 NSABP